MedPath

Effects of Low Lactose Milk Containing GOS on Digestive Response in Healthy Chinese Adults

Not Applicable
Active, not recruiting
Conditions
Healthy
Interventions
Other: Investigational Product (IP)
Other: Comparator Product (CP)
Registration Number
NCT06598124
Lead Sponsor
Société des Produits Nestlé (SPN)
Brief Summary

We are aiming to assess the effects of low lactose milk containing galactooligosaccharides (GOS) on digestive response in healthy Chinese adults in comparison with a matching milk containing lactose.

Detailed Description

This is planned to be single-center, double-blind, randomized, 2x2 cross-over study.

24 healthy participants of Chinese ethnicity are planned to be enrolled. Participants will be invited to three visit days at the research site: a screening visit and two test days, 3 to 28 days apart.

During the test days, participants will be requested, after overnight fasting, to consume either the investigational product (IP), a skimmed milk powder with low lactose content and GOS, or the comparator product (CP) a matching skimmed milk powder, both reconstituted in water. Participants will then undergo a series of tests to compare the effects of these two drinks on gastrointestinal fluid retention and motility as well as on gut comfort.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
24
Inclusion Criteria
  1. Participants declare that they are of Chinese ethnicity as well as both of their biological parents
  2. Women and men aged between 18 and 60 years
  3. Body mass index (BMI ≥ 18.5 & <30 kg/m2)
  4. Healthy: no medical conditions or previous gastrointestinal surgery which might affect study measurements (as declared by the participant)
  5. Able to understand and to sign written informed consent prior to study entry
  6. Informed consent signed
  7. Meets all the criteria for MRI Scan
  8. Can read and speak English
Exclusion Criteria
  1. Medically diagnosed milk allergy
  2. Subjects not willing and/or not able to comply with scheduled visits and the requirements of the study protocol
  3. Diagnosed with any gastrointestinal disorders
  4. History of claustrophobia
  5. Pregnant (defined by pregnancy test) or breast feeding
  6. History or current psychiatric illness
  7. History or current neurological condition (e.g. epilepsy)
  8. Consumption of > 21 alcoholic drinks in a typical week (one serving is 0.4 dl of spirits, 1 dl of wine, or 3 dl of beer as declared by participant)
  9. Currently smoking (as declared by participant)
  10. Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance
  11. Antibiotic use within the 4 weeks preceding the intervention
  12. Probiotic & prebiotics use within the 2 weeks preceding the intervention

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Arm 1Investigational Product (IP)Visit 1: Comparator Product; Visit 2: Investigational Product
Arm 1Comparator Product (CP)Visit 1: Comparator Product; Visit 2: Investigational Product
Arm 2Investigational Product (IP)Visit 1: Investigational Product; Visit 2: Comparator Product
Arm 2Comparator Product (CP)Visit 1: Investigational Product; Visit 2: Comparator Product
Primary Outcome Measures
NameTimeMethod
Small bowel water content0-315 minutes after investigational product (IP) or comparator product (CP) intake

Small bowel water content measured via MRI and calculated using the trapezoidal rule (mL\*min) at 45 minutes of interval

Gut motility0-315 minutes after IP or CP intake

Maximum gut motility after product consumption (arbitrary unit) assessed via MRI performed every 45 min

Secondary Outcome Measures
NameTimeMethod
Gastric emptying0-315 minutes after IP or CP intake

Time to empty half of the stomach contents (T1/2) (min) after product consumption assessed via MRI every 45 min

Retention rate of gastric content volumes0-315 minutes after IP or CP intake

Retention rate (RR) of gastric content volumes (GCV) calculated as the percentage of GCV in the stomach at each time point relative to the GCV measured at time 0 (%) measured via MRI every 45 min

Oro-caecal transit0-315 minutes after IP or CP intake

Time at appearance of a food bolus in the caecum (min) measured via MRI every 54 min

H2 levels0-315 minutes after IP or CP intake

Time at which the level of breath H2 shows a sustained (3 consecutive measurements) rise \> 20ppm over baseline after product consumption (min) measured every 22 min

Colonic volume0-315 minutes after IP or CP intake

Colonic volume measured by MRI every 45 min after product consumption (mL\*min)

Colonic gas production via MRI0-315 minutes after IP or CP intake

Colonic gas measured by MRI every 45 min after product consumption (arbitrary unit)

Colonic gas production via breath test0-315 minutes after IP or CP intake

Breath gas measurements (H2 and CH4) measured every 45 min after product consumption (ppm\*min)

Colonic water content0-315 minutes after IP or CP intake

Colonic water content measured via MRI every 45 minutes after product consumption (mL\*min)

T1 relaxation time0-315 minutes after IP or CP intake

T1 relaxation time of ascending colon measured measured every 45 min via MRI after product consumption (ms)

Bristol stool3 days before and after after IP or CP intake

Bowel movements \& stool consistency measured using a Bristol stool diary

GI symptoms0-315 minutes after IP or CP intake

Ordinal scoring of digestive symptoms rating via GI questionnaire composed of eight questions (score) administrated every 45 min after product consumption. Scores go from 0 to 3, 0 = not at all; 1 = mild (distinct but negligible); 2 = moderate (annoying); 3 = severe (disabling)

Trial Locations

Locations (1)

University of Nottingham

🇬🇧

Nottingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath